ArticleDermatology and therapy2024

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.

Jonathan I Silverberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.